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Abstract 
NF-κB is a transcription factor that regulates the inflammatory response, immune system, cellular 
proliferation and apoptosis. The link between NF-κB and inflammation has been shown in some studies of 
various human diseases and animal models. The activation pathway of NF-кB has been identified; 
therefore, inhibition of NF-кB is considered to be an effective therapeutic alternative in inflammatory 
diseases and cancer. Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized 
by chronic inflammation, which is also a high predisposition to colorectal cancer. The activation of NF-κB 
within the colonic epithelial cells promotes inflammation in UC by increasing the production of pro-
inflammatory cytokines, such as IL-1 and TNF-α. NF-κB also directly activates pro-survival pathway, 
which causes neo-plastic transformation, increases the expression of COX-2 induced by IL-1 and TNF-α, 
andpromotes carcinogenesis. Currently, red fruit (Pandanus conoideus Lam.) has been considered to be an 
alternative therapy of IBD, and it is proposed that red fruit could reduce the inflammation by inhibiting 
the activity of NF-κB. Previous studies have proven that red fruit has the capacity to increase the 
proliferation of immune cells. Increased lymphocyte proliferation might induce the production of anti-
inflammatory cytokines, such as IL-10 and IL-22, which subsequently inhibit the activation of NF-κB, 
COX-2, and the production of pro-inflammatory cytokines. 
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Background 
Nuclear factor κB (NF-κB) is a 
transcription factor that serves as an 
important regulator of the immune 
system, inflammatory response, cellular 
proliferation and apoptosis.1 The role of 
NF-кB in inflammation has been shown 
in some studies of various human 
diseases such as cancer, asthma, 
rheumatoid arthritis, atherosclerosis, 
and inflammatory bowel disease (IBD) .2 
NF-κB promotes inflammation by 
inducing transcription of pro-
inflammatory cytokines, cytokine 
receptors, chemokines, adhesion 
molecules, and enzymes such as matrix 
metalloproteinases (MMPs), cyclo- 
oxygenase-2 (COX-2), and inducible 
nitric oxide (iNOS).2  
The activation pathway of NF-κB 
and the factors regulating it have been 
recognized. For this reason, there is a 
considerable interest in inhibiting NF-κB 
activity for therapeutic purpose. 
However, the mechanisms responsible 
for the termination of NF-κB will not 
only affect the inflammatory response 
but will also interfere with the 
physiologic function of NF-кB, resulting 
side effects.1,2 Nowadays, new regulators 
of NF-κB have been discovered, 
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providing more selective choices in 
inhibiting NF-кB activity. 
 
The best example of inflammatory 
disease is ulcerative colitis (UC). This 
disease (UC) and Crohn disease (CD) 
have become the major forms of IBD. 
Mucosal    biopsies    from    IBD patients 
show an increased activity of NF-кB.3 In 
IBD, besides promoting inflammation, 
NF-кB also has a potential role in 
developing carcinogenesis, which may 
result in colorectal cancer (CRC). 
Therefore, the inhibition of NF-кB may 
reduce inflammation and prevent 
carcinogenesis in IBD. 
Red fruit (Pandanus conoideus Lam.) 
is a kind of fruit from Papua, Indonesia. 
Red fruit is a source of exogenous 
antioxidant, which contains a high 
amount of beta-carotene and 
tocopherol.4 In Papua, red fruit 
traditionally has been widely used to 
increase energy and immune system. 
Nowadays, red fruit is also used as anti-
inflammatory and anticancer agents in 
several diseases. Recently, several 
studies about red fruit have been 
seeding a new insight in its potential 
therapeutic effect for UC in animal 
models, but the therapeutic mechanism 
is still unclear.5,6 It is proposed that red 
fruit could reduce the inflammation by 
inhibiting NF-κB activity.  
 
 
Inflammatory Bowel Disease (IBD) 
Inflammatory bowel disease (IBD) 
is a chronic inflammation caused by 
immune system dysregulation, genetic 
susceptibility, and stimulation by 
intestinal floras.7 IBD affects 
approximately 1.4 million people in the 
United States, with an estimate annual 
cost exceeding $2 billion.3 IBD mainly 
consists of two forms, Crohn disease 
(CD) and ulcerative colitis (UC) . 8 
UC is characterized by mucosal 
damage and ulceration, which begins in 
the rectum and spreads proximally. UC 
in animal models could be induced by 
an oral administration of dextran sulfate 
sodium (DSS), which may cause direct 
toxicity to the colonic epithelial cells, 
increase cell permeability and activate 
macrophages .9 Colitis in animal models 
induced by an administration of oral 
DSS has the same appearance as UC in 
humans.10-12 The administration of 
azoxymethane (AOM) combined with 
DSS to animal models will increase the 
incidence of colorectal cancer.8,13 
  
 
The Role of NF-κB in IBD 
NF-κB activation within the colonic 
epithelial may increase the expression of 
pro-inflammatory cytokines, such as IL-1 
and TNF-α. The expression of IL-1 will 
increase the proliferation of immune 
cells, which then produce IL-6, resulting 
in neo-plastic changes.3,14  
The increased expression of COX-2 
is also found in colorectal cancer.  COX-2 
will convert arachidonic acid into 
prostaglandin (PGE2), which promotes 
angiogenesis tumor. The administration 
of TNF-α antagonist may reduce the 
expression of COX-2 in experimental 
animal models of colitis. On the 
contrary, the activation of NF-κB will 
increase the production of TNF-α, which 
will also increase the expression of COX-
2.15-18 
IL-10 is an anti-inflammatory 
cytokine that suppresses the activation 
of NF-κB, which will inhibit the 
production of pro-inflammatory 
cytokines, such as IL-1 and IL-6.19,20  IL-
22 is a super family member of IL-10, 
which is expressed by Th17 cell. IL-22 
 Inhibition of NF-κB Pathway as the Therapeutic Potential of Red Fruit  
(Pandanus conoideus Lam.) in the Treatment of Inflammatory Bowel Disease  
(Khie Khiong, Oeij Anindita Adhika, Melisa Chakravitha) 
 
 71 
plays an important role in inducing the 
expression of regulatory molecules, such 
as IL-10 and inflammatory molecules, 
such as IL-18. The administration of 
antibody anti-IL-22 may reduce the 
severity of colitis in experimental animal 
models.21 
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Figure 1. The Role of NF-кB in Inflammatory Bowel Disease. Injury to the intestinal 
epithelium can result in DNA damage and altered gene expression and function. In addition, 
this is accompanied by activation of NF-кB within the epithelial cells, which promotes 
prosurvival pathways that are required for the initial growth of resulting neoplastic cells. NF-кB 
activation also promotes proinflammatory genes expression. TNF-α originating from the mucosa 
of possibly the epithelium itself participates in the activation of immune cells. Production of 
proinflammatory factors by the activated immune system participates in the ensuing 
inflammatory response but additionaly plays a role in tumor growth by providing trophic 
signals to the early neoplastic lessions.3 
 
 
Red Fruit 
Red fruit (Pandanus conoideus Lam.) 
is also known as buah merah, tawi, or sauk 
ekendi. The fruit, which is a source of 
exogenous antioxidant, contains 
carotenoid, 7,000 ppm of beta-carotene, 
11,000 ppm of α-tocopherol, oleic acid, 
linoleic acid, decanoic acid, omega-3, 
and omega-9. The 7.000 ppm of beta-
carotene and 11.000 ppm of tocopherol 
in red fruit are considered to be a high 
amount of antioxidant.4,22  
The antioxidant in red fruit plays an 
important role in the reduction of free 
radicals produced in inflammation. The 
antioxidant also increases splenocyte 
proliferation, antibody production, 
spleen and thymus sizes.6,22,23 The 
administration of beta-carotene 30 
mg/day for 2-3 months will increase the 
number of immune cells, such as T-
lymphocyte and natural killer (NK) 
cell24,25. In addition, red fruit contains β-
cryptoxantin, which is used in lung 
cancer therapy.5  
 
 
Red Fruit as a Treatment of IBD 
Several studies have showed that 
dysregulation of the immune system and 
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lymphocytes   is    important    in    the 
pathogenesis of UC induced by DSS. The 
pin point of the previous research 
indicates that the administration of red 
fruit 0.1 ml/day for 15 days will increase 
the proliferation of lymphocyte and 
decrease IFN-γ level in Listeria 
monocytogenes- inoculated mice6. 
Moreover, the administration of red fruit 
0.1 ml/day for 3 weeks will decrease the 
severity of colitis, which is indicated by 
decreased clinical scores and increased 
proliferation of lymphocyte in colitis-
induced mice by DSS.5 
The increased proliferation of 
lymphocytes might increase the 
production of IL-10 and IL-22, which 
may inhibit the activation of NF-κB and 
the production of IL-1 and COX-2, and 
finally reduce the inflammation. The 
production of IL-10 and IL-22 is also 
expected to increase mucus production 
in colonic epithelial, which will prevent 
the development of chronic 
inflammation towards cancer. The 
suppression of NF-кB activation is 
marked by the decreasing expression of 
IκB protein. 
 
 
Activation of NF-κB 
The mammalian NF-κB family 
consists of p50 (NF-κB1), p52 (NF-κB2), 
p65 (RELA), RELB, and REL (cRel), 
which all share an amino terminal REL 
homology domain (RHD).1,2 Moreover, 
the RHD mediates the DNA binding, 
dimerization, and nuclear transport of 
the NF-κB proteins.2 Most members of 
this family can homodimerize as well as 
form heterodimers with each other. On 
the other hand, NF-κB family members 
REL, RELB, and p65 contain a 
transactivation domain (TAD), which is 
necessary for gene induction. By 
contrast, p50 and p52, which are derived 
from the inactive precursor p105 and 
p100 respectively, lack of TAD. 
Therefore, in order to promote 
transcription, p50 and p52 have to form 
heterodimers with other TAD-containing 
proteins, because as homodimers, p50 
and p52 will repress transcription when 
bound to κB-site. The most prevalent 
activated form of NF-κB is a 
heterodimer, which consists of a p50 or 
p52 subunit and p65.  
In unstimulated cells, NF-κB is 
sequestered in the cytoplasm by an 
inhibitor of NF-κB (IκB) proteins, which 
comprises three functional groups: (1) 
the typical IκB proteins IκBα, IκBβ, and 
IκBε; (2) precursors proteins p100 and 
p105; and (3) atypical IκB proteins IκBζ, 
BCL-3 (B-cell Lymphoma 3) and IκBNS.  
Following cell stimulation, IκB 
undergoes degradation by IκB Kinase 
(IKK) complex, which consists of two 
homologous kinase subunits IKKα, and 
IKKβ, and a regulatory subunit IKKγ 
(NEMO). After the degradation of IκB, 
free dimers of NF-кB translocate to the 
nucleus and bind to target genes, the 
transcription of which is regulated 
through transcriptional co-activators and 
co-repressors.1  
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Figure 2. Activation of NF-кB. An inflammatory stimulus (TNF-α, IL-1, LPS, free radicals, 
etc) activates signal transduction pathways that induce the activation of the IKK complex. This 
results in the phosphorylation of IκB proteins and consequently their degradation by the 
proteasome. Released NF-κB dimers translocate to the nucleus and bind the κB sites in the 
promoters or enhancers of target genes, which leads to their transcription.1  
 
 
Possible Mechanisms of Inhibition of 
NF-кB using Red Fruit as IBD 
Treatment 
 
Figure 3. Proposed Possible mechanisms of inhibition of NF-кB using Red Fruit. a| Red 
fruit may increase the proliferation of the immune cells, which increases the production on 
antiinflammatory cytokines IL-10 and/or  IL-22. IL-10 and IL-22 then inhibit the activity of 
proinflammatory cytokines, TNF-α and IL-1. Inhibition of TNF-α and IL-1 inhibits the activation 
of NF-κB and expression of COX-2, preventing neoplastic transformation of colonic epithelium. 
b| Red fruit may directly inhibit the expression of COX-2. c| Red fruit may directly inhibit the 
activation of NF-κB. d| Red fruit may prevent DNA damage and altered gene expression and 
function in colonic epithelium. RF: Red Fruit. 
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Conclusion 
Red Fruit (Pandanus conoideus Lam.) 
could be used as antiinflammatory and 
anticancer agents in inflammatory bowel 
disease, particularly in ulcerative colitis. 
The antioxidant in red fruit performs its 
function  either by (1) directly inhibiting 
the activation of NF-кB, (2) preventing 
DNA damage and altering gene(s) 
expression,  (3) directly inhibiting 
expression of COX-2, or (4) increasing 
the production of anti-inflammatory  
cytokines, such as IL-10 and IL-22, which 
suppress the activity of proinflammatory 
cytokines, such as TNF-α and IL-1. 
  
 
Suggestion 
Further research should be 
addressed to investigate and clarify this 
potential use of red fruit in inhibiting 
ulcerative colitis by repressing NF-кB 
activity. 
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